DK1861405T3 - Fremgangsmåde til reduktion af alfa,beta-umættede ketoner i opioidsammensætninger - Google Patents

Fremgangsmåde til reduktion af alfa,beta-umættede ketoner i opioidsammensætninger

Info

Publication number
DK1861405T3
DK1861405T3 DK06707309T DK06707309T DK1861405T3 DK 1861405 T3 DK1861405 T3 DK 1861405T3 DK 06707309 T DK06707309 T DK 06707309T DK 06707309 T DK06707309 T DK 06707309T DK 1861405 T3 DK1861405 T3 DK 1861405T3
Authority
DK
Denmark
Prior art keywords
beta
unsaturated ketones
reducing alpha
opioid compositions
reducing
Prior art date
Application number
DK06707309T
Other languages
Danish (da)
English (en)
Inventor
Robert J Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1861405T3 publication Critical patent/DK1861405T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
DK06707309T 2005-03-04 2006-02-27 Fremgangsmåde til reduktion af alfa,beta-umættede ketoner i opioidsammensætninger DK1861405T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65879105P 2005-03-04 2005-03-04
PCT/EP2006/001798 WO2006094672A1 (en) 2005-03-04 2006-02-27 Method of reducing alpha, beta unsaturated ketones in opioid compositions

Publications (1)

Publication Number Publication Date
DK1861405T3 true DK1861405T3 (da) 2009-07-20

Family

ID=36301669

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06707309T DK1861405T3 (da) 2005-03-04 2006-02-27 Fremgangsmåde til reduktion af alfa,beta-umættede ketoner i opioidsammensætninger
DK09158939.0T DK2112153T3 (da) 2005-03-04 2006-02-27 Fremgangsmåde til reduktion af alpha, beta-umættede ketoner i opioidsammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09158939.0T DK2112153T3 (da) 2005-03-04 2006-02-27 Fremgangsmåde til reduktion af alpha, beta-umættede ketoner i opioidsammensætninger

Country Status (19)

Country Link
US (1) US7939543B2 (sl)
EP (2) EP1861405B1 (sl)
JP (1) JP5314894B2 (sl)
KR (1) KR100941761B1 (sl)
CN (1) CN101133062B (sl)
AT (2) ATE487722T1 (sl)
CA (1) CA2598774C (sl)
CY (2) CY1109262T1 (sl)
DE (2) DE602006018208D1 (sl)
DK (2) DK1861405T3 (sl)
ES (2) ES2355870T3 (sl)
HK (2) HK1111695A1 (sl)
HR (2) HRP20090387T1 (sl)
ME (2) ME01594B (sl)
PL (2) PL1861405T3 (sl)
PT (2) PT1861405E (sl)
RS (2) RS51568B (sl)
SI (2) SI1861405T1 (sl)
WO (1) WO2006094672A1 (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2005016313A1 (de) * 2003-08-06 2005-02-24 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007103105A2 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
AU2007329451B2 (en) 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
AU2007329453B2 (en) * 2006-12-04 2013-04-04 Noramco, Llc Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
MX2009010931A (es) 2007-04-16 2009-10-29 Mallinckrodt Inc Reduccion novedosa de opiaceos utilizando la reaccion de transferencia catalitica de hidrogeno.
FR2923484B1 (fr) 2007-11-09 2012-11-09 Sanofi Aventis Procede de preparation de composes morphiniques
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
BR112012001244A2 (pt) * 2009-07-22 2020-12-08 Gruünenthal Gmbh Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma
ES2534908T3 (es) * 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
ES2666404T3 (es) 2010-06-11 2018-05-04 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行n-脫烷反應之方法
JP5925779B2 (ja) 2010-09-02 2016-05-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 無機塩を含む不正使用抵抗性剤形
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014140899A2 (en) 2013-03-15 2014-09-18 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
MA40332A (fr) 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812312A (en) 1971-11-15 1974-05-21 Chrysler Corp Impact velocity sensor switch with linearly movable controller
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp

Also Published As

Publication number Publication date
ATE487722T1 (de) 2010-11-15
RS51131B (sr) 2010-10-31
EP1861405B1 (en) 2009-04-29
ES2355870T3 (es) 2011-03-31
DE602006018208D1 (de) 2010-12-23
JP2008531626A (ja) 2008-08-14
JP5314894B2 (ja) 2013-10-16
SI2112153T1 (sl) 2011-02-28
HK1111695A1 (en) 2008-08-15
PT2112153E (pt) 2010-12-17
DK2112153T3 (da) 2011-02-14
EP2112153B1 (en) 2010-11-10
HK1135107A1 (en) 2010-05-28
ES2326491T3 (es) 2009-10-13
PL1861405T3 (pl) 2009-10-30
KR100941761B1 (ko) 2010-02-11
US7939543B2 (en) 2011-05-10
EP2112153A1 (en) 2009-10-28
CY1111241T1 (el) 2015-06-11
CN101133062B (zh) 2014-08-06
EP1861405A1 (en) 2007-12-05
CN101133062A (zh) 2008-02-27
ME01184B (me) 2013-03-20
ATE430153T1 (de) 2009-05-15
CY1109262T1 (el) 2014-07-02
DE602006006558D1 (de) 2009-06-10
SI1861405T1 (sl) 2009-10-31
CA2598774C (en) 2010-12-21
CA2598774A1 (en) 2006-09-14
HRP20090387T1 (en) 2009-08-31
HRP20110078T1 (hr) 2011-03-31
KR20070108931A (ko) 2007-11-13
ME01594B (me) 2014-09-20
RS51568B (en) 2011-08-31
WO2006094672A1 (en) 2006-09-14
US20080132702A1 (en) 2008-06-05
PT1861405E (pt) 2009-07-27
PL2112153T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
DK1861405T3 (da) Fremgangsmåde til reduktion af alfa,beta-umættede ketoner i opioidsammensætninger
BRPI0913457B8 (pt) Composto e composição farmacêutica
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
ATE555156T1 (de) Sauerstofffänger-mischungen
EA200970098A1 (ru) Понизитель водоотдачи для буровых растворов на масляной основе
CL2009000262A1 (es) Imidazolin-2,5 dionas bencil-benzoico sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y nicotina.
MX2011008885A (es) Composiciones, sintesis y metodos para usar derivados de arilpiperazina.
DOP2010000329A (es) Inhibidores de la renina
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BRPI0607645A2 (pt) sais de derivados de hexaidrofenantridina substituìdos com 6-heterociclila
DE602007000505D1 (de) Pulverzusammensetzungen mit Beta-Hydroxyalkylamiden von der Ringöffnung saurer Verbindungen
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
ATE514743T1 (de) Polypropylenzusammensetzung mit geringem anteil an flüchtigen elementen
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
WO2009154993A8 (en) Compositions, synthesis, and methods of using piperazine based antipsychotic agents
ATE466044T1 (de) Reduzierung flüchtiger bestandteile stabilisierter polypropylen- /talkumzusammensetzungen mithilfe einer spezifischen sauren umgebung
ATE518910T1 (de) Phenolharz-aufweisende polymerzusammensetzung
CL2009000259A1 (es) Imidazolin-2,4 dionas sustituidas con arilo, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y a la nicotina.
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
DE602006005660D1 (de) Polyester-organoeisen-zusammensetzungen
CR9693A (es) Derivados de 5-piridazinil-1-azabiciclo[3.2.1]octano, su preparacion y su aplicacion en terapeutica
ATE471963T1 (de) Reduzierung flüchtiger bestandteile stabilisierter polypropylen- /talkumzusammensetzungen mithilfe spezifischer absorptionsmittel
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.
BRPI0921091A2 (pt) Kit de formulações farmacêuticas caracterizado pela presença de oxigênio molecular.